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Modulation of interleukin-6 by b2-adrenoceptor in endotoxin- In many types of renal glomerulonephritis, macro-
stimulated renal macrophage cells. phages infiltrate into the glomerulus and interstitium,
Background. Activation of the cAMP signaling pathway by and this has been taken as being the initial step in inducingmeans of b2-adrenoceptor agonists has been shown to up-regu-
renal damage [1]. Furthermore, it has been reported thatlate interleukin-6 (IL-6) gene expression and to stimulate IL-6
macrophages are involved in the development of inter-production in macrophage cells. However, whether b2-adreno-
ceptor activation can also modify the rate of IL-6 production stitial nephritis and obstructive uropathy [2]. Although
in macrophage cells activated by the bacterial endotoxins has the mechanisms mediating the macrophage-induced re-
not yet been determined. Using renal resident macrophage cells nal damage remain unclear, the pathophysiological re-treated with endotoxin, lipopolysaccharide (LPS), and b2-adre-
sponses in these renal diseases are associated with thenoceptor agonist, terbutaline, we investigated the role of cAMP
production of proinflammatory cytokines [1], which playpathway, tumor necrosis factor (TNF)-a and mitogen-activated
protein kinase (MAPK) pathway (p42/p44) in regulating IL-6 a role in ischemia and toxic chemical injury within the
production. renal tissue [3].
Methods. IL-6 protein, mRNA, and promoter activity were
Among these proinflammatory cytokines, interleukin-6measured in these cells exposed to LPS (1 mg/ml) and/or terbu-
(IL-6) is a pleiotropic cytokine that is involved in in-taline (1029 to 1026 m). Furthermore, the time course effects
of terbutaline on cAMP, MAPK (p42/p44), and TNF-a release flammatory and immune responses, acute phase reac-
were evaluated in the cells. tions, and hematopoiesis. At the level of the kidney, IL-6
Results. Terbutaline at high concentrations (1026 m) signifi- is a key factor in mediating various components of the
cantly up-regulated IL-6 by approximately 25% (P , 0.05),
immune and inflammatory response [4]. For example,whereas at a lower concentration (1028 m), it down-regulated
IL-6 can induce the adhesion of circulating cells to theIL-6 production by 42% (P , 0.05). Terbutaline (1028 and 1026 m)
caused a concentration- and time-dependent stimulation of glomerular capillary wall [5]. It can induce proliferation
cAMP (P , 0.05) and TNF production (P , 0.05) and a time- of mesangial cells [6] and is associated with mesangial
dependent decrease in MAPK activity (P , 0.05). Following proliferative glomerulonephritis [7]. Therefore, there isthe addition of a cAMP inhibitor, IL-6 promoter activity was
a strong possibility that renal IL-6 generation is one ofcorrelated with TNF-a levels and MAPK activity.
the most important initial steps in the pathophysiologyConclusions. A biphasic effect of b2-adrenoceptor agonist
on IL-6 production in renal resident macrophage cells became of renal disease and injury [8].
apparent when LPS was exposed to the cells. The terbutaline- There is increasing evidence that activation of b2-adre-induced down-regulation of IL-6 gene production was medi- noceptors can modulate the production of lipopolysac-ated by an inhibitory effect of terbutaline on TNF-a, which
charide (LPS)-induced inflammatory cytokines, such aswas exerted through the MAPK and cAMP pathways, whereas
the up-regulation appeared to be due to a direct action of tumor necrosis factor (TNF) and IL-1, in some tissues
intracellular cAMP. and organs [9, 10], and Hetier et al have suggested that
b-adrenoceptor agonists may have an anti-inflammatory
influence on the cytokine network during the course of
the immunological responses [11]. However, the action
of b2-adrenoceptor stimulation on IL-6 production isKey words: bacterial endotoxins, cAMP, glomerulonephritis, renal in-
jury, lipopolysaccharide, ischemia. quite controversial. Liao et al observed that b2-adreno-
ceptor mediated processes increased LPS-induced IL-6Received for publication November 16, 1998
production in liver cells [9], whereas Maimone et al re-and in revised form March 23, 1999
Accepted for publication April 3, 1999 ported that exposure of astrocytes to norepinephrine
elevated IL-6, which was mediated predominantly by b2- 1999 by the International Society of Nephrology
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adrenoceptors and the activation of adenylate cyclase assay kit, and isotopes ([a-32P]dCTP, [g-32P]ATP) were
purchased from Amersham Japan (Tokyo, Japan). Un-[12]. It is recognized that intracellular cAMP plays an
important role in the stimulation of IL-6 gene expression less stated, reagents were from Sigma Chemical Co. (St.
Louis, MO, USA).[13], and it has been suggested that raised IL-6 produc-
tion caused by b2-adrenoceptor activation is mediated
Construction of reporter plasmidthrough the cAMP pathway. On the other hand, Straub
et al demonstrated that isoproterenol inhibited IL-6 se- The IL-6 promoter was amplified using Wistar rat ge-
nomic DNA as a template, which was extracted fromcretion in the spleen [14], whereas our own studies also
indicated an inhibitory effect of b2-adrenoceptor activa- spleen using a genomic DNA isolation kit. The amplifi-
cation profile of the target DNA was performed as fol-tion following LPS-induced IL-6 gene transcription in
rat astrocytes [15]. Furthermore, in an in vivo study, lows: denaturation at 948C for one minute, primer an-
nealing at 558C for one minute, and extension at 728Cepinephrine infusion into human subjects did not affect
IL-6 production following an LPS challenge [16]. These for two minutes for the first 20 cycles, followed by 30
cycles. For the first polymerase chain reaction (PCR),findings suggest that factors and/or regulatory mecha-
nisms other than the cAMP pathway contribute to b2- the upstream primer extended from 1806 to 1825 bp of
the rat IL-6 gene [17], whereas the downstream primeradrenoceptor–mediated IL-6 production. Consequently,
the mechanisms by which b2-adrenoceptor activation de- extended from 3127 to 3146 bp of the rat IL-6. For the
second PCR, the upstream primer extended from 2353termine IL-6 production both normally and in patho-
physiological states such as endotoxemia are unclear. to 2378 bp of the rat IL-6 gene [17] with an engineered
restriction for Nhe I at bp 2357, and the downstreamThis study was designed to examine the regulatory
mechanisms involved in the LPS-induced renal IL-6 pro- primer extended from 2933 to 2954 bp of the rat IL-6
with an engineered restriction for Hind III at bp 2950.duction following b2-adrenoceptor stimulation with ter-
butaline. Resident renal macrophages were challenged The amplified product was electrophoresed on a 1%
agarose gel, and a discrete band of the expected sizewith LPS, and the role of b2-adrenoceptor–mediated in-
tracellular cAMP in the regulation of IL-6 transcriptional (0.6kb) was isolated from the gel, digested with Nhe I
and Hind III, and subsequently cloned into Nhe I-Hindactivity was determined. Furthermore, because the rate
of IL-6 transcription is also dependent on the generation III of the pGV-B2 (Pica Gene basic vector-2) to generate
pGV-B2-IL-6prom. This region contains potential recog-of TNF-a, we examined the effect of b2-adrenoceptor
stimulation on mitogen-activated protein kinase (MAPK) nition sites for several transcription factors, including
the nuclear factor (NF)-kB and NF-IL-6, and comparisonactivity (p42/p44), which, in turn, contributes to the regu-
lation of TNF-a production. of the region with human IL-6 promoter revealed a high
degree of conservation. Confirmation of the identity of
the insert with the known sequence of the promoter was
METHODS
obtained by means of restriction mapping and sequenc-
Reagents ing. The sequences of these promoters were checked by
the cycle sequencing method using an automatic se-Dulbecco’s modified Eagle’s medium (DMEM), gluta-
mine, kanamycin, HEPES, antibody against b2-adreno- quencer (ABI 377).
ceptor, PD098059, and fibronectin were obtained from
Renal macrophage cells and culture conditionsCosmo Bio Corp. (Tokyo, Japan). Genomic DNA isola-
tion kits were obtained from GIBCO BRL (Life Tech- Primary cultures of resident renal macrophage cells,
including glomerular and tubular macrophages, werenologies Inc., Gaithersburg, MD, USA). pGV-B2 (Pica
Gene basic vector-2) and cell lysis buffer were from Toyo performed using a modification of the method of Cole
and de Vellis [18]. The primary cultures were initiatedInc. Corp. (Tokyo, Japan). Nhe I and Hind III were
obtained from Takara Corp. (Shiga, Japan). Fetal bovine from whole kidneys pooled from batches of newborn
Wistar rats (day 1 and 2), which were euthanized underserum (FBS) was purchased from Dainippon Pharma-
ceutical Corp. (Tokyo, Japan). Transfectam was supplied ether anesthesia. The kidneys were dissected and then
minced with a razor blade to yield 1 mm3 fragments,by Bio Sepra Inc. (Marlborough, MA, USA). The lumi-
nometer (Lumat LB953AT) was purchased from Berthold which were then resuspended gently in DMEM supple-
mented with 10% FBS, 10 mm HEPES, l-glutamine (600(Wildbad, Germany). Isogen was obtained from Nippon
Gene (Tokyo, Japan), and ICI 118,551 was obtained mg/liter), and kanamycin (100 mg/ml) and were plated
into tissue culture flask (75 cm2) precoated with fibro-from Funakoshi (Tokyo, Japan). ABI 377 was supplied
by PE-ABI Corp. (Foster City, CA, USA). Rat TNF-a nectin (0.1 mg/ml). The cells were incubated in the flask
at 378C in 5% CO2. The medium was changed everyand IL-6 enzyme-linked immunosorbent assay (ELISA)
kits were from Biosource International Inc. (Camarillo, three days, and after two weeks cells growing on top of
the confluent fibroblast monolayer were detached byCA, USA). The cAMP ELISA kit, MAPK (p42/p44)
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overnight shaking. Free cells were collected, and trypan the peptide reflected MAPK activity. Intracellular cAMP
was estimated using a commercially available ELISA kitblue was used to assess viability. Cells were replated in
in which the assay was based on the competition between25 cm2 tissue culture dishes. Macrophage purity was more
unlabeled cAMP and a fixed quantity of peroxidase-than 90% as determined by Ia induction by interferon
labeled cAMP for a limited number of binding sites on a(IFN)-g using antimouse and rat Ia monoclonal antibody
cAMP-specific antibody. Cells were lyzed using a liquid-PE conjugate. Furthermore, the cells were identified by
phase extraction method, and the supernatants weremeans of immunostaining using double labeling with b2-
used for the analysis.adrenoceptor antibody-FITC conjugate. For the study
for protein, mRNA accumulation, cAMP, and MAPK
Transfection and luciferase assay andassay, the cells (1 3 106) were incubated for up to 24
experimental protocolhours with serum-free DMEM (5 ml). For the luciferase
Transfection of pGV-B2-IL-6prom into the renal mac-assay, three hours before transfection, the cells at 3 3105
rophage cells was performed using a Transfectam kitcells were washed with phosphate-buffered saline, and
following the manufacturer’s recommendations. Thethe medium was replaced with fresh medium containing
Transfectam stock solution (15 ml) was added to tubesno serum.
containing 500 ml of complete serum-free DMEM and
vortexed. The pGV-B2-IL-6prom (4 mg) and pact b-galAnalysis of tumor necrosis factor-a and interleukin-6
plasmid (1 mg) was constructed and hence containedprotein and mRNA
b-galactosidase activity (gift from Professor M. Yama-To estimate the effect of b2-adrenoceptor stimulation
moto, The Institute of Medical Science, University ofon TNF-a and IL-6 mRNA and protein expression, su-
Tokyo, Tokyo, Japan) suspended in 500 ml of completepernatants were removed for TNF-a and IL-6 protein
serum-free DMEM and vortexed. The DNA and Trans-assay, and the cells were then collected for IL-6 mRNA
fectam stock solutions were immediately mixed and thenmeasurement. Rat TNF-a and IL-6 proteins were esti-
exposed to the cells. The Transfectam/DNA complexmated using ELISA kits according to the manufacturer’s
was left in contact with the cells for six hours, and theninstructions. We estimated mRNA levels using Northern
1 ml of DMEM containing 20% FCS was added to theblot hybridization analysis, as described in our previous
dishes for three hours. Cells were maintained in serum-study [19]. Briefly, total RNA was extracted from the
free DMEM for 24 hours prior to the experiments.cells using Isogen according to the manufacturer’s in-
For the luciferase assay, the cells were incubated forstructions. For Northern blot hybridization, the 600 bp
one or three hours with serum-free DMEM under the
Eco RI/Hind III fragment derived from the cDNA insert following conditions. To investigate the effect of the b2-of clone pGEM (a gift from Dr. S. Akira, University of adrenoceptor agonist terbutaline on the transcriptional
Osaka) for murine IL-6 and the 420 bp Hinf I fragment activity of the IL-6 gene, terbutaline (1028 or 1026 m)
for human b-actin (National Children’s Research Cen- was added with or without the LPS (1 mg/ml) challenge.
ter, Tokyo, Japan) were labeled by means of the oligo- To establish whether the effects of terbutaline were me-
labeling method in the presence of [a-32P] dCTP and diated via b2-adrenoceptors, the b2-adrenoceptor antago-used as a hybridization probe. All mRNA samples (10 nist ICI 118,551 was used. To abolish any action of intra-
mg) were simultaneously applied to a Biodyne A mem- cellular cAMP, the cAMP inhibitor (H-89, 5 3 1026 m)
brane, hybridized and exposed for the same time. The was prepared. To study the effect of cAMP on the tran-
b-actin cDNA probe was used as a loading control after scriptional activity of the IL-6 gene, an analogue of
the IL-6 probe was stripped from the membrane. cAMP, dpcAMP (1027, 1025, or 1023 m), was added to
the dishes.Measurement of mitogen-activated protein kinase
The incubated cells were harvested by adding 400 ml(p42/p44) and cAMP
of lysis buffer [10 mm Tris, 10 mm ethylenediaminetetra-
Mitogen-activated protein kinase was estimated using acetic acid (EDTA), and 150 mm NaCl, pH 8.0] at one
a commercial radioimmunoassay kit based on the or three hours after administration. The luciferase
p42/p44 MAPK-catalyzed transfer of the g-phosphate activity was measured using a luminometer (Lumat
group of adenosine 59-triphosphate to a peptide that is LB953AT) and a Pica Gene Luciferase assay system.
selective for p42/p44 MAPK. Cells were lyzed in 10 mm The luciferase activities were normalized on the basis of
Tris, 150 mm NaCl, 2 mm EGTA, 2 mm dithiothreitol, b-galactosidase activities, which were assayed as de-
1 mm orthovanadate, 1 mm phenylmethylsulfonyl fluo- scribed previously [15]. The data were expressed as the
ride, 10 mg/ml aprotinin (pH 7.4) and then centrifuged fold activation, which was calculated by dividing normal-
at 25,000 3 g for 20 minutes. The supernatant was re- ized luciferase activity (luciferase/b-galactosidase) in the
tained, as it contained the cytoplasmic MAPK. The reac- cells by the level of activity in the “control.” The experi-
tion was initiated by the addition of [g-32P] ATP at 308C ments in which transfection was performed simultane-
ously were run three times.for 30 minutes, and the rate of incorporation of 32P into
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Protocol of the study for protein, mRNA
accumulation, cAMP, and mitogen-activated
protein kinase assay
To investigate the time course effect of the b2-adreno-
ceptor agonist on IL-6 and TNF-a levels in the superna-
tant of rat renal resident macrophage cell cultures, we
measured supernatant IL-6 and TNF protein levels at 0,
1, 2, 3, 4, 6, and 24 hours after LPS (1 mg/ml) challenge
and/or terbutaline (Ter 1026 to 1029 m). To determine
whether the effects of terbutaline were mediated via
b2-adrenoceptors, the b2-adrenoceptor antagonist (ICI
118,551:ICI) was used. To abolish any action of intracel-
lular cAMP, the cAMP inhibitor (H-89, 5 3 1026 m) was
prepared. We estimated IL-6 mRNA levels at 24 hours
after LPS (1 mg/ml) challenge with or without the addi-
tion of terbutaline (Ter 1026 or 1028 m) and measured Fig. 1. Time-course of interleukin-6 (IL-6) release from the renal resi-
dent macrophage cells following the administration of the b2-adrenocep-intracellular cAMP levels at one and three hours after
tor agonist terbutaline. Cells were incubated in the presence of lipopoly-the administration of these compounds. MAPK activities saccharide (LPS; 1 mg/ml, d) alone, and LPS 1 terbutaline (Ter 1029 m,
were assayed 0, 20, 40, 60, and 80 minutes after LPS .; Ter 10–8 m, m; Ter 10–7 m, j; Ter 1026 M; s), or without any treatment
(control, h) for up to 24 hours. These drugs were added to the cells at(1 mg/ml) challenge either in the absence or presence of
the same time. Means for triplicate cultures are shown. *P , 0.05 vs.terbutaline (Ter 1026 or 1028 m). To examine the influ- IL-6 level at 24 hours in cells exposed to LPS alone.
ence of MAPK (p42/p44) inhibition on IL-6 and TNF-a
releases from the cells, LPS (1 mg/ml) was added to
the cells after 20 minutes of pretreatment with MAPK/
terbutaline exerts a biphasic effect on IL-6 productionextracellular signal-regulated kinase-1 (MEK-1) inhibi-
that was dependent on the incubation concentrationtor, PD098059 (1025 or 1026 m). IL-6 or TNF-a was mea-
when the cells were exposed to LPS. When terbutalinesured in the supernatant 24 or 3 hours after the LPS
(1026 to 1029 m) alone was given, the IL-6 level at 24challenge, respectively.
hours (terbutaline 1026 m, 21 6 5 pg/ml; 1027 m, 18 6 3
Statistics pg/ml; 1028 m, 13 6 3 pg/ml; 1029 m, 14 6 5 pg/ml)
was not changed compared with control (12 6 4 pg/ml).Statistical analysis was undertaken using analysis of
These findings were supported by observations on thevariance followed by the Bonferroni and Dunnet tests
level of cellular IL-6 mRNA (Fig. 2), in that the LPS-or Kruskal Wallis test for multiple comparisons of the
induced increase in IL-6 mRNA was significantly (P ,luciferase activity. Results were expressed as mean 6 se
0.05) greater in the presence of 1026 m terbutaline butof the mean.
was significantly depressed (P , 0.05) following the addi-
tion of 1028 m terbutaline. Under control conditions, in
RESULTS which the cells were exposed to terbutaline but without
Effects of b2-adrenoceptor stimulation on the LPS challenge, IL-6 mRNA expression was not
interleukin-6 production changed. Figure 3 shows the responses in IL-6 promoter
activity induced by LPS alone or in combination withFigure 1 shows the time course of LPS on IL-6 protein
terbutaline following one and three hour exposures ofsupernatant levels of macrophage cell cultures alone and
the cells. Exposure of the cells for one hour to the LPSin the presence of the b2-adrenoceptor agonist terbuta-
increased IL-6 promoter activity by approximately 2.7-line. Following three hours of exposure to LPS, there
fold, but this was significantly (P , 0.05) suppressed bywas a slight suppression of IL-6 levels, but at 24 hours
terbutaline in a concentration-dependent manner. Thethere was a sharp increase in production of some 45-fold.
addition of terbutaline alone at 1026 and 1028 m did notAfter a three-hour exposure to the high concentration of
change IL-6 promoter activity. Interestingly, three hoursterbutaline (1026 m), the increase in IL-6 levels induced
after the incubation with LPS, IL-6 promoter activity wasby LPS was enhanced, reaching some 57-fold increase
increased by approximately 14-fold, but when combinedat 24 hours, which was significantly greater than that
with the high concentration of terbutaline (1026 m), theachieved with LPS alone (P , 0.05). By contrast, in the
IL-6 promoter activity was significantly (P , 0.05) en-cells exposed to the low concentration of terbutaline
hanced compared with LPS alone, reaching a 21-fold(1028 m), the LPS-induced increases in IL-6 production
rise. Coincubation of LPS plus the low concentration ofwere attenuated, achieving only a 33-fold increase at 24
hours (P , 0.05). Together, these data indicate that terbutaline (1028 m) significantly (P , 0.05) depressed
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Fig. 2. Northern blot analysis of representa-
tive interleukin-6 (IL-6) and b-actin (actin)
mRNA and graph of changes in lipopolysac-
charide (LPS)-induced IL-6 mRNA units (IL-6/
b-actin mRNA) from the renal resident mac-
rophage cells in the presence and absence of
the b2-adrenoceptor agonist terbutaline. Cells
were incubated in the presence of LPS (1 mg/
ml) or LPS plus terbutaline (Ter 1026 and Ter
1028 m) for 24 hours. Numbers in (A) are: (1)
control; (2) Ter 1028 m; (3) Ter 1026 m; (4)
LPS; (5) LPS 1 Ter 1028 m; (6) LPS 1 Ter
1026 m. Means 6 se for triplicate cultures are
shown. *P , 0.05 vs. cells exposed to LPS
alone.
the LPS-induced promoter activity, achieving only a tration. It is clear that dpcAMP stimulated IL-6 promoter
ninefold increase. These changes in IL-6 promoter activ- activity in a concentration-related fashion, reaching an
ity closely corresponded to the pattern of responses ob- approximate sixfold (P , 0.05) stimulation at 1023 m
served in the protein and mRNA levels of IL-6. Under dpcAMP. Figure 5 examines the changes in endogenous
the conditions in which the LPS challenge was not given, concentration of intracellular cAMP in the cells exposed
terbutaline increased IL-6 promoter activity in a dose- to LPS alone or together with terbutaline. Terbutaline
dependent manner, although by only approximately 70% 1026 and 1028 m significantly (P , 0.05) increased intra-
(1026 m). The increases in IL-6 promoter activity induced cellular cAMP levels in a concentration-dependent man-
by the LPS plus the terbutaline were abolished using the ner, and the pattern of these responses was unaffected
b2-adrenoceptor antagonist ICI 118,551, compatible with by the presence of LPS. To further evaluate the contribu-
b2-adrenoceptors mediating these changes in IL-6 pro- tion of intracellular cAMP to the IL-6 promoter activitymoter activity in the cells; that is, not only was there
induced by terbutaline administration, an inhibitor ofpotentiation by the high concentration of terbutaline but
the cAMP-protein kinase A (PKA) pathway, H-89, wasalso attenuation by the low concentration of terbutaline.
added to the cells treated with LPS and/or terbutaline;
Intracellular cAMP and interleukin-6 the responses are shown in Figure 6. Following a one-
promoter activity hour exposure to H-89, the LPS increased IL-6 promoter
activity by some 3.5- to 4-fold, but this response wasFigure 4 shows the effect of the cAMP analogue on
IL-6 promoter activity in the cells one hour after adminis- significantly (P , 0.05) attenuated by terbutaline in a
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Fig. 4. Luciferase activities expressed by pGV-B2-IL-6prom (IL-6 pro-
moter construct) in the renal resident macrophage cells. Cells were
cultured for one hour in the presence or absence of dpcAMP (1027 to
1023 m), after which cytosolic extracts were prepared and used for the
luciferase and b-gal assays. The fold activation is the ratio of normalized
luciferase activity (luciferase/b-galactosidase) divided by the level of
the normalized activity in the untreated cells. Data are the mean 6 se
from three experiments. *P , 0.05 vs. cells exposed to dpcAMP (1027 m).
ent (Fig. 3). These findings indicate that the LPS-induced
stimulation of IL-6 promoter activity and its modulation
by b2-adrenoceptor activation seem to involve not only
intracellular cAMP but some other factors.
Suppression of MAPK (p42/p44) by terbutaline
Figure 7A shows the time course of action of terbuta-Fig. 3. Luciferase activities expressed by pGV-B2-IL-6prom (IL-6 pro-
line on MAPK (p42/p44) activity in the cells. MAPKmoter construct) in renal resident macrophage cells. Cells were cultured
in the presence or absence of terbutaline (1026 m, 1028 m), ICI 118,551 activity was stimulated by the LPS challenge, beginning
(1026 m), or LPS (1 mg/ml), after which cytosolic extracts were prepared some 20 minutes after the initial exposure, and reachedand used for the luciferase and b-gal assays. The fold activation is
a peak level at 40 minutes, of some 2.3-fold, and thenthe ratio of normalized luciferase activity (luciferase/b-galactosidase)
divided by the level of the normalized activity in the cells untreated returned to the baseline at 80 minutes. In the presence
with any regimens. Data are the mean 6 se from three experiments. of terbutaline, the peak level of LPS-induced MAPK*P , 0.05 vs. cells exposed to LPS alone.
activity at 40 minutes was suppressed. In Figure 7B, the
comparisons of MAPK activity at 40 minutes between
these groups are shown as bar graphs. Terbutaline (1026
and 1028 m) significantly (P , 0.05) suppressed MAPKconcentration-dependent manner by approximately 30
and 55% at 1028 and 1026 m (both P , 0.05), respectively, activity induced by the LPS. The terbutaline suppression
of LPS-induced MAPK activity was abolished by the b2-which was similar to the pattern of responses obtained
in the absence of H-89 (Fig. 3). However, at three hours adrenoceptor antagonist ICI 118,551, which was most
likely caused by functional b2- adrenoceptor activation.in the presence of H-89, the LPS-induced stimulation of
IL-6 promoter activity reached some 15-fold but was
Suppression of tumor necrosis factor-a by terbutalineunaffected by the 1028 m terbutaline and was depressed
by 24% (P , 0.05) in the presence of 1026 m terbutaline. Figure 8 presents the changes in supernatant levels of
TNF-a in cells treated with LPS alone or in combinationImportantly, this pattern of response was very different
from the biphasic concentration-response observed in with terbutaline. At one and three hours after exposure
to LPS, TNF-a levels were stimulated approximatelythe absence of H-89, as shown in Figure 3. Exposure of
the cells to terbutaline alone had very little influence on 3- and 23-fold, respectively, and these responses were
significantly (P , 0.05) suppressed in a concentration-IL-6 promoter activity after either one or three hours,
being comparable to that found when H-89 was not pres- related way by the terbutaline at both time points. How-
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Fig. 6. Luciferase activities expressed by the pGV-B2-IL-6prom (IL-6Fig. 5. Effects of terbutaline on intracellular cAMP concentrations in
promoter construct) in renal resident macrophage cells. After the cellsrenal resident macrophage cells at one (A) and three (B) hours after
were exposed to the cAMP inhibitor, H-89 (5 3 1026 m), they wereadministration are shown as pmol/plate (106 cells). Cells were incubated
cultured in the presence or absence of terbutaline (1026 m, 1028 m) orin the presence or absence of terbutaline (1026 m, 1028 m) or lipopolysac-
lipopolysaccharide (LPS; 1 mg/ml) for one (A) and three (B) hours,charide (LPS; 1 mg/ml) or without any treatment. Means of triplicate
after which cytosolic extracts were prepared and used for the luciferasecultures are shown. *P , 0.05 vs. cells exposed with LPS alone. †P ,
and b-gal assays. The fold activation is the ratio of normalized luciferase0.05 vs. cells without any treatment.
activity (luciferase/b-galactosidase) divided by level of the normalized
activity in the untreated cells. Data are the mean 6 se from three
experiments. *P , 0.05 vs. cells exposed to LPS alone.
ever, in the cells exposed to terbutaline alone, the TNF-a
level was not changed at either time point. In Figure 9, in
the presence of the cAMP inhibitor, H-89, LPS-induced significantly (P , 0.05) decreased IL-6 and TNF-a re-
TNF-a level was significantly suppressed by terbutaline lease from the cells following LPS stimulation (Table 1).
at both time points. The magnitude of the inhibitory Inhibition of the MAPK (p42/p44) pathway resulted in
response at three hours was small (terbutaline 1026 m, a block of the increase in IL-6 and TNF-a production
22% inhibition) compared with that found when H-89 in the cell.
was not present (1026 m, 51% inhibition; Fig. 8). Impor-
tantly, suppression of TNF-a by terbutaline partially in-
DISCUSSIONvolved the cAMP pathway, but it was also influenced by
other mechanisms. Interleukin-6 is a multifunctional cytokine whose ac-
tivities include stimulation of B-cell differentiation, sup-
Suppression of interleukin-6 and tumor necrosis porting the growth of hybridoma cell lines, and stimula-
factor-a release by MEK-1 inhibitor tion of acute phase protein production by hepatocytes.
It is recognized that IL-6 can be produced by a varietyThe potential role of the MAPK (p42/p44) in LPS
signal transduction on IL-6 and TNF-a releases was as- of cells, such as T cells, B cells, monocytes, fibroblasts,
and endothelial cells [4], whereas in the kidney, IL-6 issessed using MEK-1 inhibitor, PD098059. The inhibitor
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Fig. 8. Effect of b2-adrenoceptor stimulation on TNF-a release from
renal resident macrophage cells. Cells were cultured for one or three
hours in the presence or absence of lipopolysaccharide (LPS; 1 mg/ml)
or terbutaline (1026 m, 1028 m). Means 6 se of three experiments are
shown. *P , 0.05 vs. cells exposed to LPS alone.
Fig. 7. (A) Effect of terbutaline on mitogen-activated protein kinase
(MAPK) activities (p42/p44) in renal resident macrophage cells stimu-
lated with LPS and the time-course changes are shown. Cells were
incubated in the presence or absence of terbutaline (Ter 1026 m, s;
The important finding arising from this study was that1028 m, j) or LPS (1 mg/ml, d) or without any treatments (control,
h), for up to 90 minutes. The data are expressed as relative changes LPS was able to cause a time-dependent increase in IL-6
(fold) to level at time zero in each group. The means of triplicate protein production by rat renal resident cells. Moreover,cultures are shown. (B) Effect of terbutaline on MAPK in the cells at
the magnitude of this response was modulated by the40 minutes after LPS challenge. The data are expressed as relative
changes (fold) to level at time zero in each group. ICI 118,551 (1026 m) b2-adrenoceptor agonists in a biphasic concentration-
was used as a b2-adrenoceptor antagonist. Data are the mean 6 se from dependent way; that is, at high doses, the production ofthree experiments. *P , 0.05 vs. cells exposed to LPS alone.
IL-6 was enhanced, whereas at low doses, it was sup-
pressed. It was evident that this biphasic adrenergic mod-
ulation of IL-6 was exerted at the mRNA level, as theproduced by mesangial and vascular wall smooth muscle
increases in IL-6 mRNA in response to LPS were greatercells [20]. The production of IL-6 can be regulated by
at the high concentrations of terbutaline and less at lowTNF-a and infection, whereas enhanced IL-6 gene ex-
concentrations of terbutaline compared with that gener-pression has been observed in autoimmune diseases [4,
ated with LPS alone. The question arose as to whether21–23]. The renal resident macrophage cells can be acti-
modulation of the rate of transcription might be respon-vated by LPS and also produce IL-6, as has become
sible for the biphasic response to the b2-adrenoceptor–evident from the findings of this study, which is compati-
mediated effect. It was apparent that a complex relation-ble with the report that IL-6 increases in states of endo-
ship existed, in that following a one-hour exposure totoxemia and may be involved in inducing renal tissue
damage [8, 22]. terbutaline, there was a concentration-dependent sup-
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mediated by b2-adrenoceptors, as they were blocked by
the selective antagonist ICI 118,551, it was clear that
different mechanisms were coming into play at different
times.
These findings were intriguing in that b2-adrenoceptor
activation causes the generation of the second-messenger
cAMP and suggested that it might have multiple effects
on the rate of transcription of the IL-6 in response to
LPS. This issue was addressed by examining the action
of cAMP on IL-6 transcriptional activity, and indeed,
there was a very clear and sensitive stimulation of the
gene by the second messenger. Moreover, it was evident
that the ability of the b2-adrenoceptor agonist to increase
cellular cAMP levels was quite independent of the LPS
challenge, again suggesting that the second messenger
might be acting in more than one way to influence the
IL-6 gene expression. This view was reinforced by the
findings of the study using the cAMP inhibitor H-89.
The results showed that there was a concentration-
related inhibition of the LPS stimulation of IL-6 pro-
moter activity, which was markedly different from the
biphasic pattern of response, which was evident when
the direct effect of cAMP was investigated. Thus, it is
clear that when the cells are exposed to LPS, a range of
factors and/or other regulatory mechanisms are brought
into play, including the cAMP pathway, which would
ultimately determine the rate at which transcription of
the IL-6 gene would occur.
One important and potent factor that is strongly and
specifically induced by LPS is TNF-a, and its biosynthetic
regulation seems to be exerted at several levels. TheFig. 9. Effect of b2-adrenoceptor stimulation on TNF-a release from
signaling pathway used by LPS to induce TNF-a biosyn-renal resident macrophage cells following inhibition of the cAMP path-
way. After the cAMP inhibitor H-89 (5 3 1026 m) was added to the thesis is believed to be dependent on the activation of
dishes, the cells were cultured for one (A) or three (B) hours in the tyrosine kinases [24]. Tyrosine kinase-initiating pro-presence or absence of LPS (1 mg/ml) or terbutaline (1026 m, 1028 m).
cesses often involve the subsequent activation of theMeans 6 se of three experiments are shown. *P , 0.05 vs. cells exposed
to LPS alone. MAPK signaling pathway, and one of the initial LPS-
stimulated events is the phosphorylation and activation
of the p42/p44 isoforms of MAPK (p42/p44) pathwayTable 1. Modulation of LPS-induced IL-6 and TNF-a release from
rat resident macrophage cells by an MEK-1 inhibitor (PD098059) [25]. In this study, an enhanced MAPK (p42/p44) activity
was detected within 20 minutes of cellular stimulation,IL-6 TNF-a
which was short lived, and the activity decreased to a
pg /ml
basal level within 80 minutes, which was compatible with
Control 1665 3165 previous reports [26]. Furthermore, we were able to show
LPS 22368 775631
that suppression of MAPK (p42/p44) pathway usingLPS 1 PD098059 1026 m 18265a 591632a
LPS 1 PD098059 1025 m 149610a 347631a PD098059 resulted in a decreased release of IL-6 and
Lipopolysaccharide (LPS 1 mg/ml) was added in the cells after 20 minutes of TNF-a from the cells. These observations support an
pre-treatment with PD098059. Interleukin (IL)-6 or tumor necrosis factor earlier report [27] that suppression of MAPK (p42/p44)(TNF)-a released during the following 24 or 3 hours was measured by ELISA,
respectively. The results were the means 6 se of three separate experiments. pathway diminished LPS-induced IL-6 mRNA and IL-6
a P , 0.05 vs. LPS production in liver Kupffer cells. The findings of this
study extended these observations and demonstrated
that b2-adrenoceptor activation suppressed MAPK (p42/
p44) pathway in the cells, which, in turn, was correlatedpression in the IL-6 promoter activity to LPS, but at
three hours, there was an enhanced response at the high with a decreased TNF-a levels and reduction in IL-6 pro-
duction. Vanden-Berghe et al indicated that the NF-kBand a depressed response at the low concentration of
terbutaline. Although both patterns of responses were was involved in the regulation of IL-6 gene expression
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by TNF-a [28]. Following a one-hour exposure to terbu- cAMP and/or MAPK (p42/p44) pathways. Furthermore,
other mechanisms and intracellular signals may be alsotaline, the LPS-induced IL-6 promoter activity was sup-
pressed and correlated with the decreases in MAPK ac- involved with the modulation of LPS-induced IL-6 pro-
duction by b2-adrenoceptor activation.tivity and TNF-a. The effect of terbutaline on IL-6
promoter activity was not influenced by the addition of
H-89, which would suggest that the decrease in LPS- ACKNOWLEDGMENTS
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cellular cAMP levels [10, 11, 29]. Olivier et al found that
Abbreviations used in this article are: DMEM, Dulbecco’s modified
an increase in intracellular cAMP concentration decreased Eagle’s medium; IL-6, interleukin-6; LPS, lipopolysaccharide; MAPK,
mitogen-activated protein kinase; MEK-1, MAPK/extracellular signal-the NF-kB–mediated function of TNF-a gene transcrip-
regulated kinase-1; NF, nuclear factor; PKA, protein kinase A; TNF,tion and IL-6 production [30]. This suggests that the
tumor necrosis factor.
cAMP pathway leads to an inhibition of TNF levels, which
indirectly would decrease IL-6 production, whereas a
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